قارن الطرق

	استبيان نايميخن للتنفس الوظيفي المضطرب	مقياس مجلس البحوث الطبية لضيق التنفس
المجال	طب الرئة	طب الرئة
العائلة	Process / pipeline	Process / pipeline
سنة النشأة	1994	1959
صاحب الطريقة	van Beveren and colleagues, Netherlands	Medical Research Council (UK)
النوع	Self-report questionnaire	Clinician or self-rated ordinal scale
المصدر التأسيسي	Van Beveren, T. L., Fülöp, M., van Beek, H. G., & Zijlstra, F. J. (1994). Hyperventilation and panic panic attacks in a group of asthma patients. Respiration, 61(5), 282-287.	Van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Schouten, H. J., & van Gijn, J. (1988). Interobserver agreement for the assessment of handicap in stroke patients. Stroke, 19(5), 604-607.
الأسماء البديلة	Nijmegen, Nijmegen Questionnaire, DBQ	MRC, MRC Dyspnea, Modified Borg
ذات صلة	5	5
الملخص	The Nijmegen Questionnaire is a 16-item self-report instrument designed to identify dysfunctional breathing patterns, particularly hyperventilation syndrome, in patients presenting with respiratory or non-respiratory symptoms. Developed by van Beveren and colleagues in the Netherlands in 1994, it provides rapid assessment of symptoms attributable to chronic hyperventilation: dizziness, chest tightness, muscle tension, paresthesias, and anxiety. The Nijmegen Questionnaire is widely used in respiratory physiology clinics, pulmonary rehabilitation programs, and psychosomatic medicine to detect dysfunctional breathing phenotypes that may masquerade as asthma, anxiety disorders, or cardiopulmonary disease.	The MRC Dyspnoea Scale is a simple 5-grade ordinal classification of dyspnea severity based on the exertional threshold at which breathlessness limits activity. Developed by the UK Medical Research Council (MRC) in 1959, it remains one of the most widely used dyspnea assessments globally due to its brevity, ease of administration, and strong prognostic correlation in chronic obstructive pulmonary disease and other chronic respiratory diseases. The scale is used in clinical practice, epidemiological surveys, and longitudinal disease monitoring to grade symptom severity and guide treatment intensity.